核心结合因子或NPM1突变急性髓系白血病患者一线强化治疗后的分子学复发——一项FILO研究
该回顾性研究纳入303例18-60岁、首次完全缓解后未接受异基因造血干细胞移植、接受一线强化治疗并进行了分子学监测的核心结合因子(CBF)或NPM1突变急性髓系白血病(AML)患者。153例(51%)从未复发,95例(31%)发生分子学复发(其中53例接受抢先治疗,42例进展为形态学复发后接受挽救治疗),55例(18%)直接形态学复发。接受抢先治疗者总生存(OS)优于分子学复发进展后挽救治疗者及直接形态学复发者(3年OS:78% vs 51% vs 51%,P=0.01)。
要点
- 分子学监测可发现CBF或NPM1突变AML的分子学复发,抢先治疗者3年OS为78%。
- 分子学复发后进展为形态学复发再挽救治疗者3年OS为51%,直接形态学复发者亦为51%。
- 抢先治疗方式包括异基因HCT(19例)、强化化疗(21例)和非强化治疗(13例),3年OS分别为92%、79%和58%(P=0.09)。
核心结论
- 尽管因复发时治疗策略的非随机分配而结论非决定性,本研究提示应考虑在随访中进行分子学监测,以便在明显形态学复发前开始抢先治疗。
研究设计与样本
- 回顾性分析303例18-60岁、首次完全缓解后未接受异基因造血细胞移植(HCT)、一线强化治疗后接受分子学监测的CBF或NPM1突变AML患者。
主要发现
- 153例(51%)从未复发,95例(31%)发生分子学复发(53例接受抢先治疗,42例进展为形态学复发后接受挽救治疗),55例(18%)直接形态学复发。
- 抢先治疗者3年OS为78%,分子学复发进展后挽救治疗者为51%,直接形态学复发者为51%(P=0.01)。
- 抢先治疗包括异基因HCT(19例)、强化化疗(21例)和非强化治疗(13例),3年OS分别为92%、79%和58%(P=0.09)。
临床怎么用
- 作者建议:应考虑在随访中进行分子学监测,以便在明显形态学复发前开始抢先治疗。
局限性
- 因复发时治疗策略的非随机分配,结论非决定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with Core-Binding Factor (CBF) and NPM1-mutated acute myeloid leukemia (AML) can be monitored by quantitative PCR after having achieved first complete remission (CR) to detect morphologic relapse and drive preemptive therapy. How to best manage these patients is unknown. We retrospectively analyzed 303 patients with CBF and NPM1-mutated AML, aged 18-60 years, without allogeneic hematopoietic cell transplantation (HCT) in first CR, with molecular monitoring after first-line intensive therapy. Among these patients, 153 (51%) never relapsed, 95 (31%) had molecular relapse (53 received preemptive therapy and 42 progressed to morphologic relapse at salvage therapy), and 55 (18%) had upfront morphologic relapse. Patients who received preemptive therapy had higher OS than those who received salvage therapy after having progressed from molecular to morphologic relapse and those with upfront morphologic relapse (three-year OS: 78% vs. 51% vs. 51%, respectively, P = 0.01). Preemptive therapy included upfront allogeneic HCT (n = 19), intensive chemotherapy (n = 21), and non-intensive therapy (n = 13; three-year OS: 92% vs. 79% vs. 58%, respectively, P = 0.09). Although not definitive due to the non-randomized allocation of patients to different treatment strategies at relapse, our study suggests that molecular monitoring should be considered during follow-up to start preemptive therapy before overt morphologic relapse.
引用
- Orvain C, Bertoli S, Peterlin P, et al. Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study. Leukemia. 2024. PMID: 39020060. doi:10.1038/s41375-024-02335-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。